China’s first anti COVID-19 specific drug was approved for sale, effective for many variants such as delta

This approval is based on the phase 3 clinical trial of activ-2 supported by the National Institutes of Health (NIH), including the positive interim and final results of 847 enrolled patients. The final results showed that compared with placebo, ambacizumab / romisizumab combination therapy could reduce the risk of hospitalization and death in high-risk new crown outpatients by 80% (the interim result was 78%), which was statistically significant